Skip to main content
. 2014 Sep 11;9(9):e106901. doi: 10.1371/journal.pone.0106901

Figure 6. Cross-talk between angiogenic growth factors.

Figure 6

Basal, VEGF-, bFGF-, or EGF-driven cords were treated with a VEGFR-2 antibody (IMC-1121B; Ramucirumab; Ram), a bFGF antibody (anti-bFGF), or an EGFR inhibitor (Gefitinib) and the percent inhibition of total tube area from the ArrayScan was graphed. n = 3 per group.